It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. Asia Pacific AstraZeneca Biotechnology China Deals Focus On Immuno-oncology Junshi ... Immuno-oncology company Affimed made further gains in Tuesday’s market following its 9% jump on Monday. A broad pipeline of next-generation medicines is focused principally on four disease areas - breast, ovarian, lung and hematological cancers. AstraZeneca still hopes to gain an important foothold in the immuno-oncology market with a combination treatment that mixes two of its pipeline medicines, durvalumab and tremelimumab. AstraZeneca and Merck Will Independently Develop and Commercialize LYNPARZA and Potential Medicine Selumetinib in Combinations with Companies’ Respective PD-L1/PD-1 Immuno-Oncology Medicines IMFINZI and KEYTRUDA . AstraZeneca still hopes to gain an important foothold in the immuno-oncology market with a combination treatment that mixes two of its pipeline medicines, durvalumab and tremelimumab. Checkpoint inhibitor drugs, a type of immunotherapy, have revolutionised cancer treatment in the last decade, showing outstanding clinical results in patients with solid tumours. AstraZeneca’s vision in Oncology is to help patients by redefining the cancer-treatment paradigm, with the aim of bringing six new cancer medicines to patients between 2013 and 2020. AstraZeneca’s Iannone sees it rather differently, arguing that the durable response generated by I-O drugs makes long-term survival, not PFS, the gold standard test. In cancer research, AstraZeneca focuses on four primary scientific platforms — immuno-oncology, tumor drivers and resistance, DNA damage response, and antibody-drug conjugates. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, … About MedImmune MedImmune is the worldwide biologics research and development arm of AstraZeneca. These are being targeted through four key platforms – immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates. AstraZeneca still hopes to gain an important foothold in the immuno-oncology market with a combination treatment that mixes two of its pipeline medicines, durvalumab and tremelimumab. AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.